New cancer drug enters first human trials
NCT ID NCT06115642
Summary
This is the first human study of an experimental cancer drug called HLX43. Researchers are testing its safety and how it moves through the body in 340 adults with advanced solid tumors that have spread or don't respond to standard treatments. The study will find the safest dose and see if the drug shows any early signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
Contact
-
Xiangya Hospital Central South University
RECRUITINGChangsha, Hu'Nan, 410008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.